<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828516</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000632850</org_study_id>
    <secondary_id>LJMC-AMWELL-SL</secondary_id>
    <secondary_id>EU-20903</secondary_id>
    <nct_id>NCT00828516</nct_id>
  </id_info>
  <brief_title>Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema</brief_title>
  <acronym>AMWELL-SL</acronym>
  <official_title>Using Acupuncture and Moxibustion to Promote Wellbeing and Improve Quality of Life for Patients With Upper Body Lymphoedema Secondary to Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East and North Hertfordshire NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Vernon Cancer Centre at Mount Vernon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Lymphoedema Framework</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lymphoedema Support Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>East and North Hertfordshire NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients
      with lymphedema caused by breast cancer or head, neck, and throat cancer.

      PURPOSE: This clinical trial is studying how well acupuncture given together with moxibustion
      works in improving well-being and quality of life in patients with breast cancer or head,
      neck, and throat cancer who are undergoing standard treatment for lymphedema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To test the acupuncture and moxibustion treatment strategies to obtain a first measure
           of response for the approach(es) used in patients with breast cancer or head, neck, and
           throat cancer undergoing standard treatment for secondary lymphedema.

        -  To assess whether this treatment is an acceptable intervention to cancer patients with
           secondary lymphedema and to their health care professionals.

        -  To disseminate the data to begin to build the evidence base for using this treatment in
           the management of lymphedema.

      OUTLINE: Patients undergo acupuncture and moxibustion therapy once weekly for 7 treatment
      (Series 1). After completion of therapy, patients may choose to continue treatment for an
      additional 6 treatments (Series 2).

      Patients complete a set of 4 questionnaires (i.e., sociodemographic, Short-Form-36, Positive
      and Negative Affect Scale (PANAS), and Measure Yourself Medical Outcome Profile (MYMOP)) at
      the first treatment and then periodically during study. Patients also complete a series of
      follow-up questionnaires designed to elicit feedback about their acupuncture experience.

      After completion of study treatment, patients are followed at 1 and 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile (MYMOP)</measure>
    <time_frame>Before 7th acupuncture treatment</time_frame>
    <description>MYMOP is a questionnaire widely used for evaluating interventions based on holistic and participative principles. It enables respondants to specify and measure the treatment outcomes that are important to them.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile</measure>
    <time_frame>Before the 13th acupuncture treatment</time_frame>
    <description>MYMOP is a questionnaire widely used for evaluating interventions based on holistic and participative principles. It enables respondants to specify and measure the treatment outcomes that are important to them.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Usual treatment plus acupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acupuncture and moxibustion</intervention_name>
    <description>Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.</description>
    <arm_group_label>Usual treatment plus acupuncture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  male or female patients with either breast or head and neck cancer

          -  diagnosis of mild to moderate uncomplicated lymphoedema

          -  age 18 or over

          -  under the care of the lymphoedema service for at leas:

          -  two months (head and neck cancer patients)

          -  three months (breast cancer patients)

          -  no active cancer disease

          -  at least 3 months since prior active cancer treatment (surgery, radiotherapy,
             chemotherapy, intravenous treatment)

          -  more than 6 months since prior acupuncture treatment

          -  concurrent adjuvant hormonal therapy allowed

          -  concurrent anti-depressant medication allowed provided there has been no change in
             prescription or dosing within the past 3 months and patient intends to remain on the
             medication for the duration of study treatment and follow-up

          -  Able to understand and communicate in English

          -  Able to travel to the Lynda Jackson Macmillan Centre for treatment

          -  Able to attend treatment once weekly for at least 7 consecutive weeks

          -  Able to complete outcome measures

        EXCLUSION CRITERIA:

          -  bilateral breast cancer

          -  advanced cancer disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverley de Valois, PhD LicAc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynda Jackson Macmillan Centre at Mount Vernon Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lynda Jackson Macmillan Centre at Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>de Valois B and Peckham R (2011) Treating the person and not the disease: acupuncture in the management of cancer treatment-related lymphoedema. European Journal of Oriental Medicine, 6(6), 37-49.</citation>
  </reference>
  <results_reference>
    <citation>de Valois BA, Young TE, Melsome E. Assessing the feasibility of using acupuncture and moxibustion to improve quality of life for cancer survivors with upper body lymphoedema. Eur J Oncol Nurs. 2012 Jul;16(3):301-9. doi: 10.1016/j.ejon.2011.07.005. Epub 2011 Sep 13.</citation>
    <PMID>21917515</PMID>
  </results_reference>
  <results_reference>
    <citation>de Valois B, Young T, Melsome E (2011) Acupuncture in lymphoedema management: a feasibility study. Journal of Lymphoedema. 6(2) 20-31.</citation>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <results_first_submitted>November 9, 2012</results_first_submitted>
  <results_first_submitted_qc>December 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 17, 2013</results_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East and North Hertfordshire NHS Trust</investigator_affiliation>
    <investigator_full_name>Beverley de Valois PhD LicAc FBAcC</investigator_full_name>
    <investigator_title>Research Acupuncturist</investigator_title>
  </responsible_party>
  <keyword>lymphedema</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage I mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage I verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage II adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage II mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage II verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I basal cell carcinoma of the lip</keyword>
  <keyword>stage II basal cell carcinoma of the lip</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland acinic cell tumor</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>salivary gland adenoid cystic carcinoma</keyword>
  <keyword>salivary gland anaplastic carcinoma</keyword>
  <keyword>salivary gland malignant mixed cell type tumor</keyword>
  <keyword>salivary gland poorly differentiated carcinoma</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage I salivary gland cancer</keyword>
  <keyword>stage II salivary gland cancer</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment: June 2008 though May 2009. Participants recruited via the Mount Vernon Hospital Lymphoedema Service.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clinical Phase</title>
          <description>Breast cancer and head and neck cancer patients with lymphoedema secondary to cancer treatment. Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by a further 6 treatments (Series 2) if participant wishes to continue treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Clinical Phase: Series 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Clinical Phase: Series 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clinical Phase</title>
          <description>Breast cancer and head and neck cancer patients with lymphoedema secondary to cancer treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile (MYMOP)</title>
        <description>MYMOP is a questionnaire widely used for evaluating interventions based on holistic and participative principles. It enables respondants to specify and measure the treatment outcomes that are important to them.</description>
        <time_frame>Before 7th acupuncture treatment</time_frame>
        <population>All participants completing 6 acupuncture treatments were analysed</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Plus Traditional Acupuncture</title>
            <description>All participants were considered stable and were undergoing maintenance treatment for lymphoedema, and were receiving adjunctive acupuncture treatment to promote wellbeing and improve quality of life</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile (MYMOP)</title>
          <description>MYMOP is a questionnaire widely used for evaluating interventions based on holistic and participative principles. It enables respondants to specify and measure the treatment outcomes that are important to them.</description>
          <population>All participants completing 6 acupuncture treatments were analysed</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>There will be no improvement in MYMOP profile score after 6 acupuncture treatments.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This was not adjusted for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.51</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>MYMOP uses a 7-point scale, from 0 to 6, with &quot;0&quot; as good as it can be, and &quot;6&quot; as bad as it can be. Higher values represent a worse outcome.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile</title>
        <description>MYMOP is a questionnaire widely used for evaluating interventions based on holistic and participative principles. It enables respondants to specify and measure the treatment outcomes that are important to them.</description>
        <time_frame>Before the 13th acupuncture treatment</time_frame>
        <population>This was the number of participants who continued to, and completed, Series 2 of the treatments</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care Plus Traditional Acupuncture</title>
            <description>All participants were considered stable and were undergoing maintenance treatment for lymphoedema, and were receiving adjunctive acupuncture treatment to promote wellbeing and improve quality of life</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient-specified and Reported Symptoms on the Measure Yourself Medical Outcome Profile</title>
          <description>MYMOP is a questionnaire widely used for evaluating interventions based on holistic and participative principles. It enables respondants to specify and measure the treatment outcomes that are important to them.</description>
          <population>This was the number of participants who continued to, and completed, Series 2 of the treatments</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>There will be no improvement in MYMOP profile score after 12 treatments</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.32</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <estimate_desc>MYMOP uses a 7-point scale, from 0 to 6, with &quot;0&quot; as good as it can be, and &quot;6&quot; as bad as it can be. Higher values represent a worse outcome.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Usual Care Plus Traditional Acupuncture</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Beverley de Valois</name_or_title>
      <organization>Lynda Jackson Macmillan Centre</organization>
      <phone>+44(0)1923-844456</phone>
      <email>beverley.devalois@nhs.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

